Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-001 in Androgenetic Alopecia
NCT07618195Phase 2Recruiting
- Sponsor
- Epibiotech
- Start
- Jan 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 2, randomised trial in androgenetic alopecia (AGA) comparing EPI-001 with Placebo (2 arms). Primary endpoint: Incidence of Dose-Limiting Toxicities at 4 weeks. Started Jan 2026; status: recruiting.
02
Drugs
EPI-001
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT07618195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07618195.